Literature DB >> 19662361

Wortmannin inhibits K562 leukemic cells by regulating PI3k/Akt channel in vitro.

Qing Wu1, Yan Chen, Guohui Cui, Yiquan Cheng.   

Abstract

The inhibitory effect of wortmannin on leukemic cells and the possible mechanisms were examined. K562 cells were treated with wortmannin of various concentrations (3.125-100 nmol/L) for 0-72 h. MTT assay was used to evaluate the inhibitory effect of wortmannin on the growth of K562 cells. Cell apoptosis was detected by both Annexin-V FITC/PI double-labeled cytometry and transmission electron microscopy (TEM). The expression of p-Akt, T-p-Akt, NF-kappaBp65 and IKK-kappaB was determined by Western blotting and reverse transcription-polymerase chain reaction (RT-PCR). Our results showed that wortmannin obviously inhibited growth and induced apoptosis of K562 cells in vitro in a time- and dose-dependent manner. The IC(50) value of wortmannin for 24 h was 25+/-0.14 nmol/L. Moreover, wortmannin induced K562 cells apoptosis in a dose-dependent manner. TEM revealed typical morphological changes of apoptosis in wortmannin-treated K562 cells, such as chromatin condensation, karyopyknosis, karyorhexis and apoptotic bodies. Additionally, several important intracellular protein kinases such as p-Akt, NF-kappaBp65 and IKK-kappaB experienced degradation of various degrees in a dose-dependent manner both at protein level and transcription level when cultured with wortmannin, but the expression of total Akt showed no change. It is concluded that wortmannin can inhibit the proliferation and induce apoptosis of K562 leukemia cells possibly by down-regulating the survival signaling pathways (PI3K/Akt and NF-kappaB channels).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19662361     DOI: 10.1007/s11596-009-0412-x

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  23 in total

Review 1.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Authors:  Jian-Min Tang; Quan-Ying He; Rui-Xia Guo; Xiu-Jun Chang
Journal:  Lung Cancer       Date:  2006-02       Impact factor: 5.705

3.  Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma.

Authors:  Kazuaki Nakanishi; Michiie Sakamoto; Susumu Yamasaki; Satoru Todo; Setsuo Hirohashi
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

4.  Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.

Authors:  Birgitte B Olsen; Marina Bjørling-Poulsen; Barbara Guerra
Journal:  Int J Biochem Cell Biol       Date:  2006-08-30       Impact factor: 5.085

5.  Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.

Authors:  Suzanne D Westfall; Michael K Skinner
Journal:  Mol Cancer Ther       Date:  2005-11       Impact factor: 6.261

6.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways.

Authors:  V L Grandage; R E Gale; D C Linch; A Khwaja
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

7.  Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

Authors:  Prince George; Purva Bali; Srinivas Annavarapu; Anna Scuto; Warren Fiskus; Fei Guo; Celia Sigua; Gautam Sondarva; Lynn Moscinski; Peter Atadja; Kapil Bhalla
Journal:  Blood       Date:  2004-10-28       Impact factor: 22.113

Review 8.  Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.

Authors:  Amit Panwalkar; Srdan Verstovsek; Francis J Giles
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

Review 9.  Nuclear factor-kappa B and cancer: its role in prevention and therapy.

Authors:  Alok C Bharti; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

10.  Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.

Authors:  Yongde Liao; Rainer Grobholz; Ulrich Abel; Lutz Trojan; Maurice Stephan Michel; Peter Angel; Doris Mayer
Journal:  Int J Cancer       Date:  2003-11-20       Impact factor: 7.396

View more
  5 in total

1.  Down-regulation of p110β expression increases chemosensitivity of colon cancer cell lines to oxaliplatin.

Authors:  Weicheng Liu; Guihua Wang; Xiaonian Cao; Xuelai Luo; Zhaoming Li; Yu Deng; Xiaolan Li; Shijia Wang; Mengfei Liu; Junbo Hu; Jing Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

2.  Wortmannin induces MCF-7 breast cancer cell death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen species, and membrane blebbing.

Authors:  Rozina Akter; Md Zakir Hossain; Maurice G Kleve; Michael A Gealt
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-07-13

3.  Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1.

Authors:  Hongye Ma; Lei Cheng; Keji Hao; Yanping Li; Xiaobo Song; Huimin Zhou; Li Jia
Journal:  PLoS One       Date:  2014-01-16       Impact factor: 3.240

4.  Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.

Authors:  Hsien-Chuen Soo; Felicia Fei-Lei Chung; Kuan-Hon Lim; Veronica Alicia Yap; Tracey D Bradshaw; Ling-Wei Hii; Si-Hoey Tan; Sze-Jia See; Yuen-Fen Tan; Chee-Onn Leong; Chun-Wai Mai
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

5.  A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models.

Authors:  Weijin Wang; Qiuzhi Zhou; Tao Jiang; Shihong Li; Jinwang Ye; Jie Zheng; Xin Wang; Yanchao Liu; Minmin Deng; Dan Ke; Qun Wang; Yipeng Wang; Jian-Zhi Wang
Journal:  Theranostics       Date:  2021-03-11       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.